ARNA - ARNA STOCK NEWS

Arena Pharmaceuticals (Nasdaq: ARNA) announced the granting of inducement stock options and restricted stock units (RSUs) to 20 new employees. The stock options allow the purchase of 33,340 shares at an exercise price of $59.09, the stock's closing price on September 15, 2021. The options have a seven-year term and vest over four years. RSUs, totaling 15,655, will vest similarly over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to support Arena's mission of delivering essential medicines to patients.

Arena Pharmaceuticals (Nasdaq: ARNA) announced two virtual R&D Investor calls focusing on its etrasimod programs. The first call, on September 21, 2021, at 10:30 a.m. ET, will cover gastroenterology, featuring speakers Robert Lisicki and William Sandborn. The second call is set for September 27, 2021, at 11:00 a.m. ET, focusing on dermatology with Doug Manion and Jonathan Silverberg. Additionally, Arena will participate in five investor conferences throughout September.

Arena Pharmaceuticals (Nasdaq: ARNA) announced the granting of stock options, performance restricted stock units (PRSUs), and restricted stock units (RSUs) to new employees as an inducement for their employment. The Compensation Committee approved these grants on August 10, 2021, with a grant date of August 15, 2021. Notably, the grants included stock options for 90,000 shares and RSUs for 15,000 shares to Doug Manion, Executive VP of Research and Development. The stock options have a seven-year term with an exercise price of $48.12, vesting over four years.

Arena Pharmaceuticals (Nasdaq: ARNA) reported its Q2 2021 financial results, highlighting a net loss of $146.1 million, up from $84.9 million in Q2 2020. Research and development expenses increased to $112.5 million, primarily due to advancing clinical studies. The company announced full enrollment in the Phase 3 ELEVATE UC 12 trial for etrasimod in ulcerative colitis, with data expected in Q1 2022. Additionally, a partnership with Aristea was formed to enhance the immunology pipeline. Cash reserves stood at $1 billion as of June 30, 2021.

Second Genome announced a strategic collaboration with Arena Pharmaceuticals (ARNA) on August 5, 2021, aimed at identifying microbiome biomarkers linked to clinical responses for etrasimod, a treatment for Crohn's disease. Utilizing its sg-4-sight platform, Second Genome will analyze data from Arena's CULTIVATE clinical trial. This partnership intends to improve patient stratification and treatment optimization. Second Genome is advancing its pipeline of precision therapies in inflammatory bowel disease and cancer, expecting clinical development to commence in 2022.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will announce its second quarter 2021 financial results on August 5, 2021, post U.S. market close. The company plans a live webcast at 4:30 PM ET to discuss these results with investors. Arena emphasizes its commitment to delivering crucial medicines while adapting to market changes. The press release includes forward-looking statements regarding corporate updates and potential risks, with a cautionary note about factors that may lead to differing actual results.

Arena Pharmaceuticals and Aristea Therapeutics have entered into a strategic collaboration focused on RIST4721, an oral CXCR2 antagonist for treating palmoplantar pustulosis (PPP). Arena will pay $60 million upfront and invest $10 million in Aristea's Series B financing. In return, Arena gains an exclusive option to acquire Aristea after completing a Phase 2b study of RIST4721. This partnership may also explore treatments for additional neutrophil-mediated diseases. Aristea recently secured $63 million in Series B financing.

Arena Pharmaceuticals (Nasdaq: ARNA) announced the granting of inducement stock options and restricted stock units (RSUs) to 17 new employees on July 16, 2021. A total of 45,200 stock options and 20,235 RSUs were issued, with stock options priced at $64.33 per share, equal to the closing stock price on the grant date. The options vest over four years, with 25% vesting after one year, and the remaining 75% vesting monthly. The RSUs also have a four-year vesting schedule. This grant complies with Nasdaq Listing Rule 5635(c)(4).

Arena Pharmaceuticals (Nasdaq: ARNA) announced the appointment of Douglas J. Manion as Executive Vice President of Research & Development. Dr. Manion, who has over 20 years in the pharmaceutical industry, will report to Amit D. Munshi, President and CEO. His previous roles include CEO of Kleo Pharmaceuticals and Senior Vice President at Bristol-Myers Squibb. Arena has a diversified pipeline targeting gastroenterology, dermatology, and cardiology, including four investigational medicines across eight indications and eleven clinical trials.